Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025)

Marker Therapeutics (MRKR) has disclosed Current Deferred Revenue for 3 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a N/A change, with the full-year FY2021 number at $1.1 million, changed N/A from a year prior.
  • Current Deferred Revenue was $1.4 million for Q3 2025 at Marker Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q2 2025 to a low of $107530.0 in Q3 2023.
  • A 3-year average of $989916.5 and a median of $1.2 million in 2021 define the central range for Current Deferred Revenue.